MXCT
MaxCyte, Inc. NASDAQ Listed Jul 30, 2021$1.19
-0.42%
vs $1.20
Mkt Cap $127.5M
52w Low $0.64
44.8% of range
52w High $1.86
50d MA $1.23
200d MA $1.10
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.1x
ROE
-26.0%
P/FCF
-3.5x
RSI (14)
45.90
ATR (14)
$0.06
Beta
1.45
50d MA
$1.23
200d MA
$1.10
Avg Volume
673.3K
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
9713 Key West Avenue · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMC | -0.09 | -0.08 | +11.1% | 1.27 | -7.9% | +9.4% | -5.0% | +0.0% | -3.8% | +9.4% | — |
| May 12, 2026 | AMC | -0.10 | -0.04 | +60.0% | 0.82 | +14.3% | +24.1% | +6.9% | -4.6% | +1.9% | -1.9% | — |
| Mar 24, 2026 | AMC | -0.08 | -0.06 | +25.0% | 0.74 | -1.4% | -6.8% | +3.9% | -4.6% | -1.1% | +3.9% | — |
| Nov 12, 2025 | AMC | -0.11 | -0.12 | -9.1% | 1.58 | -3.8% | -4.4% | +4.6% | +3.2% | +4.9% | -0.6% | — |
| Aug 6, 2025 | AMC | -0.10 | -0.12 | -20.0% | 2.04 | -16.7% | -29.9% | -3.5% | -4.3% | -3.8% | +8.7% | — |
| May 7, 2025 | AMC | -0.10 | -0.10 | +0.0% | 2.74 | -10.6% | -11.3% | -2.9% | -3.8% | -3.1% | +0.0% | — |
| Mar 11, 2025 | AMC | -0.12 | -0.10 | +16.7% | 3.47 | -10.4% | -8.4% | -3.8% | +7.5% | -0.9% | -2.1% | — |
| Nov 6, 2024 | AMC | -0.13 | -0.11 | +15.4% | 3.88 | +3.4% | -10.8% | -2.0% | +5.6% | -1.1% | +0.3% | — |
| Aug 6, 2024 | AMC | -0.14 | -0.09 | +35.7% | 4.45 | +4.0% | -8.3% | +2.5% | +0.0% | -3.6% | +0.2% | — |
| May 7, 2024 | AMC | -0.14 | -0.09 | +35.7% | 3.93 | +0.3% | +18.1% | +1.9% | +0.2% | -0.6% | -3.6% | — |
| Mar 12, 2024 | AMC | -0.10 | -0.05 | +50.0% | 3.98 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% | — |
| Nov 8, 2023 | AMC | -0.10 | -0.11 | -10.0% | 3.35 | -3.0% | -3.3% | +1.5% | +5.8% | +6.6% | +0.8% | — |
| Aug 9, 2023 | AMC | -0.10 | -0.10 | +0.0% | 4.36 | -7.3% | -10.3% | -1.8% | +0.0% | -0.8% | -4.2% | — |
| May 10, 2023 | AMC | -0.11 | -0.11 | +0.0% | 4.65 | -12.5% | -19.8% | +2.7% | -1.3% | -2.4% | +3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Craig-Hallum | Maintains | Buy → Buy | — | $0.74 | $0.73 | -1.4% | -6.8% | +3.9% | -4.6% | -1.1% | +3.9% |
| Aug 11 | BTIG | Downgrade | Buy → Neutral | — | $1.38 | $1.36 | -1.4% | -4.3% | -3.8% | +8.7% | +2.2% | -3.5% |
| Aug 7 | William Blair | Downgrade | Outperform → Market Perform | — | $2.04 | $1.70 | -16.7% | -29.9% | -3.5% | -4.3% | -3.8% | +8.7% |
| Mar 12 | Stifel | Maintains | Buy → Buy | — | $3.47 | $3.11 | -10.4% | -8.4% | -3.8% | +7.5% | -0.9% | -2.1% |
| Apr 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.96 | $3.97 | +0.3% | -4.0% | -1.6% | -1.3% | +0.5% | -1.3% |
| Mar 13 | BTIG | Maintains | Buy → Buy | — | $3.98 | $4.05 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% |
| Mar 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.98 | $4.05 | +1.8% | +4.5% | +1.0% | +2.6% | -3.2% | +7.0% |
| Oct 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.27 | $2.53 | -22.6% | -20.5% | +10.0% | +5.2% | +1.7% | -2.3% |
| Mar 28 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.11 | $4.12 | +0.2% | -0.7% | +8.1% | +6.6% | +5.3% | -3.2% |
| Aug 15 | BTIG | Maintains | Buy → Buy | — | $5.87 | $5.85 | -0.3% | -2.0% | +7.3% | -2.8% | -0.7% | -5.7% |
| Aug 24 | BTIG | Maintains | Buy → Buy | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | Stifel | Maintains | Buy → Buy | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | TD Cowen | Maintains | Outperform → Outperform | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
| Aug 24 | William Blair | Maintains | Outperform → Outperform | — | $14.34 | $14.40 | +0.4% | -2.6% | -2.2% | +2.9% | +12.4% | -3.0% |
No insider trades available.
8-K · 2.02
!! High
MaxCyte, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A leadership transition to a new CFO effective March 30, 2026 signals potential strategic shifts in financial management and capital allocation that investors should monitor for signs of operational changes or guidance updates.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K/FD disclosure suggests MXCT shared non-material information with investors that won't trigger liability, indicating no significant news requiring incorporation into formal filings.
Mar 24
8-K
Unknown — 8-K Filing
Maxcyte faces delisting risk from Nasdaq unless its stock price recovers above minimum bid requirements, threatening market access and investor confidence.
Mar 20
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 8,867,386 | $14M | Reduced | Dec 2025 |
| 2 | Capricorn Fund Managers Ltd | 8,200,000 | $10M | — | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 4,031,284 | $5M | Added | Jun 2026 |
| 4 | Blackrock, Inc. | 3,060,960 | $4M | New | Jun 2026 |
| 5 | Brooklands Fund Management Ltd | 2,848,083 | $4M | Added | Jun 2026 |
| 6 | Vitruvian Partners Llp | 5,043,356 | $4M | — | Mar 2026 |
| 7 | Bnp Paribas Asset Management Holding S.a. | 2,773,554 | $3M | — | Jun 2026 |
| 8 | Peapod Lane Capital Llc | 2,125,752 | $3M | Added | Jun 2026 |
| 9 | Mudita Advisors Llp | 3,370,689 | $2M | — | Mar 2026 |
| 10 | Renaissance Technologies Llc | 1,910,800 | $2M | Reduced | Jun 2026 |
| 11 | Aqr Capital Management Llc | 1,882,776 | $2M | Added | Jun 2026 |
| 12 | Citadel Advisors Llc | 1,712,636 | $2M | Added | Jun 2026 |
| 13 | Two Sigma Investments, Lp | 1,462,941 | $2M | Added | Jun 2026 |
| 14 | Millennium Management Llc | 1,204,921 | $1M | Added | Jun 2026 |
| 15 | Willis Investment Counsel | 862,758 | $1M | — | Jun 2026 |
| 16 | Jane Street Group, Llc | 528,025 | $818K | Added | Dec 2025 |
| 17 | Northern Trust Corp | 799,709 | $562K | Added | Mar 2026 |
| 18 | Point72 Asset Management, L.p. | 299,853 | $369K | New | Jun 2026 |
| 19 | Nano Cap New Millennium Growth Fund L P | 230,000 | $356K | New | Dec 2025 |
| 20 | George Kaiser Family Foundation | 481,803 | $338K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$127.5M
Enterprise Value
$23.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.48x
P/B
0.74x
P/S
4.11x
P/FCF
-3.50x
EV/EBITDA
—
Shares Out
106.4M
Financials (TTM)
Revenue
$31.1M
Net Income
-$35.6M
EBITDA
-$32.5M
Free Cash Flow
-$36.2M
Op Cash Flow
-$34.4M
EPS Basic
$-0.42
EPS Diluted
$-0.33
EPS Forward
$-0.26
Gross Margin
79.4%
Op Margin
-111.6%
Net Margin
-114.8%
Balance Sheet
Total Assets
$202.5M
Total Liab.
$31.0M
Total Equity
$171.5M
Cash
$103.0M
LT Debt
$0
Book Value/Sh
$1.61
Debt/Equity
0.10x
Current Ratio
8.30
Quick Ratio
7.77
Returns & Growth
ROE
-26.0%
ROA
-22.0%
ROIC
-23.0%
Rev Growth YoY
-14.5%
EPS Growth YoY
-7.7%
Price Returns
2W
-5.6%
1M
-14.4%
3M
+0.8%
6M
+58.1%
12M
-21.7%
Technicals
52W High
$1.86
52W Low
$0.64
50d MA
$1.23
200d MA
$1.10
RSI (14)
45.90
ATR (14)
$0.06
Beta
1.45
Avg Volume
673K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 26, 2026 1:59pm
· Source: financialmodelingprep.com